Merck & Co.'s Barr To Lead Clinical Development After Baynes Departs For Eikon
Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.
You may also be interested in...
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.
Frazier has answered the call from Roger Perlmutter, his former head of R&D at Merck, to help the mysterious new biotech develop its platform.